［1］ RAJKUMAR SV.Multiple myeloma:2020 update on diagnosis,risk-stratification and management［J］.Am J Hematol,2020,95(5):548-567.
［2］ DE JONG MME,KELLERMAYER Z,PAPAZIAN N,et al.The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape［J］.Nat Immunol,2021,22(6):769-780.
［3］ GARCIA-ORTIZ A,RODRIGUEZ-GARCIA Y,ENCINAS J,et al.The role of tumor microenvironment in multiple myeloma development and progression［J］.Cancers (Basel),2021,13(2):217.
［4］ HOSEN N.Integrins in multiple myeloma［J］.Inflamm Regen,2020,40:4.
［5］ JANISZEWSKA M,PRIMI MC,IZARD T.Cell adhesion in cancer:Beyond the migration of single cells［J］.J Biol Chem,2020,295(8):2495-2505.
［6］ LI M,WANG Y,LI MW,et al.Integrins as attractive targets for cancer therapeutics［J］.Acta Pharm Sin B,2021,11(9):2726-2737.
［7］ LEY K,RIVERA-NIEVES J,SANDBORN WJ,et al.Integrin-based therapeutics:Biological basis,clinical use and new drugs［J］.Nat Rev Drug Discov,2016,15(3):173-183.
［8］ KOLASANGIANI R,BIDONE TC,SCHWARTZ MA.Integrin conformational dynamics and mechanotransduction［J］.Cells,2022,11(22):3584.
［9］ DOTAN I,ALLEZ M,DANESE S,et al.The role of integrins in the pathogenesis of inflammatory bowel disease:Approved and investigational anti-integrin therapies［J］.Med Res Rev,2020,40(1):245-262.
［10］ DOYLE AD,NAZARI SS,YAMADA KM.Cell-extracellular matrix dynamics［J］.Phys Biol,2022,19(2):ac4390.
［11］ CHEN JR,ZHAO JT,XIE ZZ.Integrin-mediated cancer progression as a specific target in clinical therapy［J］.Biomed Pharmacother,2022,155:113745.
［12］ MEZU-NDUBUISI OJ,MAHESHWARI A.The role of integrins in inflammation and angiogenesis［J］.Pediatr Res,2021,89(7):1619-1626.
［13］ COHEN K,ELLIS M,KHOURY S,et al.Thyroid hormone is a MAPK-dependent growth factor for human myeloma cells acting via alphavbeta3 integrin［J］.Mol Cancer Res,2011,9(10):1385-1394.
［14］ RIA R,VACCA A,RIBATTI D,et al.Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma［J］.Haematologica,2002,87(8):836-845.
［15］ BOU ZERDAN M,NASR L,KASSAB J,et al.Adhesion molecules in multiple myeloma oncogenesis and targeted therapy［J］.Int J Hematol Oncol,2022,11(2):IJH39.
［16］ NERI P,BAHLIS NJ.Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma［J］.Curr Cancer Drug Targets,2012,12(7):776-796.
［17］ BARCZYK M,CARRACEDO S,GULLBERG D.Integrins［J］.Cell Tissue Res,2010,339(1):269-280.
［18］ WAGNER N,MULLER W.Functions of alpha 4-and beta 7-integrins in hematopoiesis,lymphocyte trafficking and organ development［J］.Curr Top Microbiol Immunol,1998,231:23-32.
［19］ NOLTE M,MARGADANT C.Controlling immunity and inflammation through integrin-dependent regulation of TGF-beta［J］.Trends Cell Biol,2020,30(1):49-59.
［20］ SHAIN KH,YARDE DN,MEADS MB,et al.Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells:Implications for microenvironment influence on tumor survival and proliferation［J］.Cancer Res,2009,69(3):1009-1015.
［21］ SEVILLA-MOVILLA S,ARELLANO-SANCHEZ N,MARTINEZ-MORENO M,et al.Upregulated expression and function of the alpha4beta1 integrin in multiple myeloma cells resistant to bortezomib［J］.J Pathol,2020,252(1):29-40.
［22］ KOBUNE M,CHIBA H,KATO J,et al.Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism［J］.Mol Cancer Ther,2007,6(6):1774-1784.
［23］ FURUKAWA Y,KIKUCHI J.Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma［J］.Int J Hematol,2016,104(3):281-292.
［24］ SOLIMANDO AG,MALERBA E,LEONE P,et al.Drug resistance in multiple myeloma:Soldiers and weapons in the bone marrow niche［J］.Front Oncol,2022,12:973836.
［25］ STEFANICH EG,DANILENKO DM,WANG H,et al.A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes［J］.Br J Pharmacol,2011,162(8):1855-1870.
［26］ MANSOOR A,AKHTER A,POURNAZARI P,et al.Protein expression for novel prognostic markers (Cyclins D1,D2,D3,B1,B2,ITGbeta7,FGFR3,PAX5) correlate with previously reported gene expression profile patterns in plasma cell myeloma［J］.Appl Immunohistochem Mol Morphol,2015,23(5):327-333.
［27］ OHGUCHI H,HIDESHIMA T,BHASIN MK,et al.The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival［J］.Nat Commun,2016,7:10258.
［28］ NERI P,REN L,AZAB AK,et al.Integrin beta7-mediated regulation of multiple myeloma cell adhesion,migration,and invasion［J］.Blood,2011,117(23):6202-6213.
［29］ SALAMA Y,HEIDA AH,YOKOYAMA K,et al.The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical models［J］.Blood Adv,2020,4(6):1021-1037.
［30］ COHEN K,ELLIS M,SHINDERMAN E,et al.Relevance of the thyroid hormones-alphavbeta3 pathway in primary myeloma bone marrow cells and to bortezomib action［J］.Leuk Lymphoma,2015,56(4):1107-1114.
［31］ NOBORIO-HATANO K,KIKUCHI J,TAKATOKU M,et al.Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma［J］.Oncogene,2009,28(2):231-242.
［32］ MICHAEL M,PARSONS M.New perspectives on integrin-dependent adhesions［J］.Curr Opin Cell Biol,2020,63:31-37.
［33］ HOSEN N.Chimeric antigen receptor T-cell therapy for multiple myeloma［J］.Int J Hematol,2020,111(4):530-534.
［34］ ZUNDLER S,SCHILLINGER D,FISCHER A,et al.Blockade of alphaEbeta7 integrin suppresses accumulation of CD8(+) and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo［J］.Gut,2017,66(11):1936-1948.
［35］ STEINMAN L.Blocking adhesion molecules as therapy for multiple sclerosis:Natalizumab［J］.Nat Rev Drug Discov,2005,4(6):510-518.
［36］ YOUSRY TA,MAJOR EO,RYSCHKEWITSCH C,et al.Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy［J］.N Engl J Med,2006,354(9):924-933.
［37］ YOSHIMURA N,WATANABE M,MOTOYA S,et al.Safety and efficacy of AJM300,an oral antagonist of alpha4 Integrin,in induction therapy for patients with active ulcerative colitis［J］.Gastroenterology,2015,149(7):1775-1783 e1772.